Key takeaway
In a small trial of 50 women having chemotherapy for breast cancer, 12 weeks of home-based moderate walking improved perceived cognitive function versus usual care, but not attention, executive function, memory or visuospatial skills on objective tests. The abstract gives no numbers for the effect, and the sample is small.
Study design
Randomised trial
Reading basis
Published abstract
Reading focus
Comparator & uncertainty
The research question
Many people treated with chemotherapy for breast cancer notice, and tests can detect, problems with thinking and concentration. Walking has helped cognition in other groups, so the authors tested whether a self-managed moderate walking programme could protect thinking in this setting.
Who and how
Randomised controlled trial of 50 breast cancer patients, randomised mid-way through chemotherapy to a home-based, self-managed programme of 12 weeks of moderate-intensity walking (n = 25) or usual care (n = 25). Perceived cognition was measured with the Cognitive Failures Questionnaire (CFQ); objective cognition with the Stroop test, Sustained Attention to Response Task (SART), and the Digit Span and Block Design subscales of the WAIS. The abstract does not report scores, effect sizes or walking adherence.
What it found
The authors’ reported results. Read each estimate with its population and uncertainty.
- 1Compared with usual care, the walking group showed positive effects on perceived (self-rated) cognitive function.
- 2No benefit was found on sustained attention, executive function, memory or visuospatial skills when measured with neuropsychological tests.
- 3The abstract reports no effect sizes, confidence intervals or P values for either result, so the size of the self-rated benefit cannot be judged.
Limits & uncertainty
- 1With 25 women per group the trial is small, and the authors themselves call for larger samples to assess cognition objectively.
- 2Self-rated cognition cannot be hidden from participants who know they are walking, so expectation may have shaped the positive result.
- 3The mismatch between self-rated and objective results means the walking may have changed how people felt about their thinking more than how they performed.
- 4This reading is based on the abstract only, which gives no numbers.
What to take from it
Walking during chemotherapy may help you feel your thinking is sharper, but this small trial did not show better performance on cognitive tests. Anyone having chemotherapy should check with their oncology team before starting an exercise plan.
Reading your own data
If your care team approves, daily steps or walking minutes from a wearable are an easy way to keep a regular walking routine. Compare weekly averages on the same device, and note how you feel alongside the numbers, since the study found a perceived rather than a measured benefit.
How to read this evidence
Randomisation can support causal inference, but check allocation, blinding, missing outcomes, follow-up and the actual comparator. A trial label alone does not establish high certainty.
Authors’ structured abstract English
The attributed English abstract is reproduced under the recorded open licence. It is source material, not a MoveVitals interpretation. The prepared analysis above separates the authors’ findings from our interpretation.
Background
Cancer related cognitive impairments have been subjectively reported and objectively detected in breast cancer patients treated with chemotherapy and are known to have a profound negative impact on productivity, psychosocial well-being and overall quality of life. Moderate levels of walking are known to be of benefit to the psychosocial well-being of those affected by breast cancer and for managing cognitive impairment in healthy adults, children, and the elderly. The purpose of this study is to investigate the effects of a home-based, self-managed, moderate intensity walking intervention on subjective and objective cognitive functioning in breast cancer patients undergoing chemotherapy.
Methods
A home-based, self-managed intervention that consisted of moderate levels of walking was compared to usual care among breast cancer patients treated with chemotherapy in a randomised controlled trial. Outcome measures included changes in subjective (CFQ) and objectively detected cognitive functioning (Stroop, SART and two subscales from the WAIS- Digit Span and Block Design). Fifty participants were randomised to either the intervention group (n = 25), who completed 12 weeks of moderate intensity walking, or to the control group (n = 25) mid-way through chemotherapy.
Results
Compared with the control group, the self-managed walking intervention had positive effects on perceived cognitive function but not on sustained attention, executive function, memory or visual spatial skills when assessed objectively using neuropsychological measures.
Conclusion
This home-based, self-managed intervention is beneficial for protecting against perceived cognitive decline in breast cancer patients treated with chemotherapy. There is a need for further research to objectively assess cognitive decline within this population with larger sample sizes of patients.
Trial registration
Current Controlled Trials ISRCTN50709297.
Sources & attribution
Does walking protect against decline in cognitive functioning among breast cancer patients undergoing chemotherapy? Results from a small randomised controlled trial.
Gokal K, Munir F, Ahmed S, Kancherla K, Wallis D.
PloS one · 2018-11-28
DOI: 10.1371/journal.pone.0206874 ↗PubMed · 30485297 ↗Europe PMC · Recorded licence: cc by ↗Abstract © the original authors, reproduced under the recorded open licence. Translations support reading; use the English record to check terminology and numerical results. Our methodological interpretation is separate from the authors’ conclusions.
MoveVitals editorial interpretation · educational content · no individual clinical review recorded
Sources checked 2026-11-01
Practical guides
Read in context
Exercise gave small-to-moderate cognitive gains across 133 reviews of trials
An umbrella review of 133 systematic reviews (2724 trials, 258,279 participants) found that exercise improved general cognition (SMD 0.42, 95% CI 0.37 to 0.47), memory (0.26) and executive function (0.24), with the largest memory gains in children and adolescents and the largest executive function gains in people with ADHD. Most of the reviews (94) were rated critically low in quality and the effects were smaller in the best-rated ones (0.23 for general cognition), and the outcomes were test scores, not dementia.
British Journal of Sports Medicine
More daily steps linked to fewer depressive symptoms across 33 studies of adults
Pooling 33 observational studies of 96,173 adults, higher daily step counts went with fewer depressive symptoms, and in the two prospective cohorts that could be pooled, 7000 or more steps a day went with a lower risk of depression than fewer (RR 0.69, 95% CI 0.62-0.77). Most studies were cross-sectional, so low mood may be reducing steps as much as steps affect mood, and the authors say the prediction intervals call for caution.
JAMA Network Open
Exercise eased depression in 218 trials, but confidence in the evidence is low
In a network meta-analysis of 218 trials with 14,170 people who met criteria for major depression, walking or jogging, yoga, strength training, mixed aerobic exercise and tai chi or qigong each gave moderate reductions in depression compared with active controls (walking or jogging: Hedges' g −0.62, 95% credible interval −0.80 to −0.45). Confidence in the evidence was low for walking or jogging and very low for the other treatments, mainly because only one study met the low-risk-of-bias criteria.
BMJ
Physical activity eased depression and anxiety across 97 reviews of trials
Across 97 systematic reviews that pooled 1039 randomized trials with 128,119 participants, physical activity had medium effects on depression (median effect size −0.43) and anxiety (−0.42) compared with usual care, and higher-intensity activity went with larger gains. Most of those reviews (77) were rated critically low in quality, and the evidence mainly concerns mild-to-moderate symptoms.
British Journal of Sports Medicine

